The Silverstein Foundation for
EIN 820656623Total Given 2022–2024
$4.5M
12 grants · $1.5M avg/year
based on 3 yrs of IRS 990-PF records on file
$1M+/yr
mid-tier
capacity
$225K
typical big bets · $199K–$364K
grant size
10%
transactional · 1/10 multi-year
repeat
$241K
Assets (2024)
10
Distinct Recipients
Focus Areas
Application Information
Accepts Unsolicited Proposals
Unknown
Contact Person
THE SILVERSTEIN FOUNDATION FOR PARK
Phone
(917) 519-8108
Deadlines
THE FOUNDATION REVIEWS QUALIFIED GRANT APPLICATIONS AS RECEIVED.
How to Apply
THE FOUNDATION'S BOARD OF TRUSTEES AND SCIENTIFIC ADVISORY COMMITTEE ACCEPT GRANT APPLICATIONS FROM ORGANIZATIONS FOCUSED ON RAPIDLY CONVERTING SCIENTIFIC IDEAS AND EXPERIMENTAL DRUGS INTO FDA APPROVED THERAPEUTICS TO TREAT AND PREVENT THE ONSET OF PARKINSON'S DISEASE IN GBA-MUTATION CARRIERS.
Restrictions
NONE
Financial Trends
Giving Over Time
Total Assets Over Time
View financial data as table
| Year | Total Giving | Total Assets | Revenue | Grants |
|---|---|---|---|---|
| 2022 | $2.6M | $1.5M | $49K | 5 |
| 2023 | $1.8M | $321K | $626K | 6 |
| 2024 | $75K | $241K | $26K | 1 |
Grant Size Distribution
Based on 12 grants on record
Minimum
$75K
25th Pctl
$199K
Median
$225K
Average
$374K
75th Pctl
$364K
Maximum
$1.4M
Geographic Distribution
Officers & Directors
JS
Jonathan Silverstein
3+ yrs
President / Chair of Board
Leadership
NS
Natalie Silverstein
3+ yrs
Vice President / Secretary
Leadership
GL
Geoffrey Levin
3+ yrs
Board Member
NS
Natalie Silverstein
3+ yrs
Vice President / Secretary
Leadership
JS
Jonathan Silverstein
3+ yrs
President / Chair of Board
Leadership
GL
Geoffrey Levin
3+ yrs
Board Member
JS
Jonathan Silverstein
3+ yrs
President / Secretary
Leadership
NS
Natalie Silverstein
3+ yrs
Vice President / Treasurer
Leadership
GL
Geoffrey Levin
3+ yrs
Board Member
Grants Awarded (12 total)
| Purpose | ||||
|---|---|---|---|---|
| The New York Stem Cell Foundation | New York, NY | $1,372,500 | DRUG DISCOVERY FOR PARKINSON'S WITH GBA. | 2022 |
| The New York Stem Cell Foundation | New York, NY | $627,500 | DRUG DISCOVERY FOR PARKINSON'S WITH GBA | 2022 |
| The New York Stem Cell Foundation | New York, NY | $627,500 | DRUG DISCOVERY FOR PARKINSON'S WITH GBA | 2023 |
| Tel Aviv Sourasky Medical Center | Tel Avivyafo, None | $276,000 | THE ROLE OF THE IMMUNE SYSTEM IN GLUOCEREBROSIDASE (GBA)-PD: A CSF AND PBMC STUDY | 2023 |
| Sunnybrook Research Institute | Toronto, None | $250,000 | A PHASE I/II STUDY FOR BILATERAL PUTAMENAL DELIVERY OF RECOMBINANT GLUCOCEREBROSIDASE IN PATIENTS WITH... | 2023 |
| Lysoway Therapeutics | Cambridge, MA | $225,000 | EVALUATING THE THERAPEUTIC EFFECTS OF TRPML1 AND TMEM175 AGONISTS ON GBA-DEFICIENT PARKINSON'S DISEASE MODELS. | 2022 |
| Curasen Therapeutics | San Mateo, CA | $225,000 | GENOTYPING AND BIOMARKER ANALYSES IN CLINICAL STUDY CLIN-015 | 2022 |
| Curasen Therapeutics | San Carlos, CA | $225,000 | GENOTYPING AND BIOMARKER ANALYSES IN CLINICAL STUDY | 2023 |
| Michael J Fox Foundation Modag | New York, NY | $200,000 | FOLLOW-UP STUDY OF A DRUG (ANLE138B) - GOAL IS TO STOP THE PARKINSON'S PROTEIN ALPHA-SYNUCLEIN (A-SYN) FROM... | 2022 |
| The Chancellor Masters and Scholars of the University of Oxford | Oxford, None | $195,000 | SUPPORT ONE MOVEMENT DISORDERS FELLOW FOR A TWO-YEAR PERIOD WHO HAS A FOCUS ON GBA-PARKINSON'S DISEASE RESEARCH... | 2023 |
| Hamad Bin Khalifa University | Arrayyan, None | $190,000 | THERAPEUTIC NANOBODY DEVELOPMENT FOR TARGETING ALPHA-SYNUCLEIN AGGREGATION IN PARKINSON'S DISEASE, WITH FOCUS ON... | 2023 |
| Baylor College of Medicine | Huston, TX | $75,000 | THE SILVERSTEIN FELLOWSHIP. | 2024 |